Patents by Inventor Julia Philip

Julia Philip has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200405674
    Abstract: The present invention relates to the use of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate to increase cellular availability of calcium in living cells of the epidermis and to a specific mixture of such components and a formulation consisting of said mixture and a solvent.
    Type: Application
    Filed: February 20, 2020
    Publication date: December 31, 2020
    Applicant: Merck Patent GmbH
    Inventors: Alexander Paul SCHILLER, Lisa ECKELHOEFER, Julia BLEIFUSS, Andrew Philip SALAZAR, Joerg von HAGEN
  • Publication number: 20200407351
    Abstract: The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. The invention is in a preferred embodiment concerned with compounds of the general formula (I), wherein the substituents R1 to R15 have the meanings as provided in claim 1 and depending claims.
    Type: Application
    Filed: September 21, 2017
    Publication date: December 31, 2020
    Inventors: Florian KLOSS, Sebastian SCHIEFERDECKER, Axel BRAKHAGE, Julia DREISBACH, Marvin J. MILLER, Ute MOLLMANN, Kamil Philip WOJTAS
  • Patent number: 10809264
    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: October 20, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt
  • Patent number: 10670500
    Abstract: There is provided a system (10) and method (100) for improving ICC and/or ISH rare cell detection by lowering background noise and providing enhanced detection of rare cells (15). In an embodiment, background noise for an ICC and/or an ISH rare cell detection assay is reduced and rare cell signaling is enhanced via feedback control. To accomplish the feedback control, an electronic control circuit (24) can direct a fluid delivery apparatus (18) to add an adjustment amount to account for fluid loss in the system (10) when fluid loss is indicated.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 2, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt
  • Patent number: 10604751
    Abstract: Nucleic acids in non-rare cells in a sample containing non-rare cells and rare cells are selectively released from the non-rare cells. The sample is combined with an aqueous medium, and the combination is held for a period of time and at a temperature for selectively releasing nucleic acids from the non-rare cells but not from the rare cells. The sample is subjected to filtration to separate rare cells from non-rare cells. Rare cells with intact nucleic acids are separated from non-rare cells and nucleic acids from the non-rare cells. Nucleic acids from the rare cells are subjected to one or more identification techniques either with or without extraction of nucleic acids from the rare cells.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 31, 2020
    Assignee: Siemens Healthcare Disgnostics Inc.
    Inventors: Michael Pugia, Julia Philip, Karen Marfut
  • Publication number: 20170137805
    Abstract: Nucleic acids in non-rare cells in a sample containing non-rare cells and rare cells are selectively released from the non-rare cells. The sample is combined with an aqueous medium, and the combination is held for a period of time and at a temperature for selectively releasing nucleic acids from the non-rare cells but not from the rare cells. The sample is subjected to filtration to separate rare cells from non-rare cells. Rare cells with intact nucleic acids are separated from non-rare cells and nucleic acids from the non-rare cells. Nucleic acids from the rare cells are subjected to one or more identification techniques either with or without extraction of nucleic acids from the rare cells.
    Type: Application
    Filed: July 2, 2015
    Publication date: May 18, 2017
    Inventors: Michael Pugia, Julia Philip, Karen Marfut
  • Publication number: 20170131191
    Abstract: There is provided a system (10) and method (100) for improving ICC and/or ISH rare cell detection by lowering background noise and providing enhanced detection of rare cells (15). In an embodiment, background noise for an ICC and/or an ISH rare cell detection assay is reduced and rare cell signaling is enhanced via feedback control. To accomplish the feedback control, an electronic control circuit (24) can direct a fluid delivery apparatus (18) to add an adjustment amount to account for fluid loss in the system (10) when fluid loss is indicated.
    Type: Application
    Filed: July 2, 2015
    Publication date: May 11, 2017
    Applicant: SIEMENS HEALTHCARE DIGANOSTICS INC.
    Inventors: Michael Pugia, Julia Philip, Karen Marfut
  • Publication number: 20170102390
    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
    Type: Application
    Filed: May 29, 2015
    Publication date: April 13, 2017
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt
  • Publication number: 20170038389
    Abstract: Provided herein are methods of screening a patient sample in a circulating tumor cell assay for false positives as well as methods of performing a circulating tumor cell detection assay. Also provided herein are methods of simultaneously identifying, and methods of distinguishing between, a circulating tumor cell and a circulating endothelial cell in a patient sample. Methods of treating a patient with cancer comprising screening for false positives in a circulating tumor cell assay and administering to the patient an anti-cancer therapy are further provided.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 9, 2017
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt